November 6, 2021
OncoHost: Personalizing cancer treatment based on host response
Original source here.
Israeli company analyzes proteomic changes after cancer treatment to identify resistance pathways and generate navigation system for clinicians
OncoHost is developing a platform to predict the host response to a cancer therapy, which could enable personalized treatment strategies, improve outcomes and reduce side effects.
OncoHost Ltd. founder Yuval Shaked, who is an Israel Institute of Technology professor and head of the Technion Integrated Cancer Center, has investigated how individuals physiologically react to cancer treatment, called the host response, for 15 years